Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C

Clinical Therapeutics

Volumn 34, Issue 10, 2012, Pages 2021-2038

  Chang, Mei H ^a   Gordon, Lori A ^a   Fung, Horatio B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Boceprevir; Direct acting antiviral agent; Nonstructural protein 3 serine protease inhibitor; SCH 503034

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ALOPECIA; ANEMIA; ANOREXIA; CHILL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; EMBASE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEPATITIS C; HUMAN; HYPERPYREXIA; INSOMNIA; LIMIT OF DETECTION; MEDLINE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; THROMBOCYTOPENIA; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84867375586     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.08.009     Document Type: Review

References (79)

1. Daniels D., Grytdal S., Wasley A. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009, 58:1-27. Centers for Disease Control and Prevention (CDC).
2. Workowski K.A., Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59(RR-12):1-110. Centers for Disease Control and Prevention (CDC), [published correction appears in MMWR Recomm Rep. 2011;60:18].
3. Desai A.P., Reau N. Naives, nonresponders, relapsers: who is there left to treat?. Clin Liver Dis 2011, 15:483-495.
4. Foote B.S., Spooner L.M., Belliveau P.P. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother 2011, 45:1085-1093.
5. Jazwinski A.B., Muir A.J. Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterol Clin North Am 2011, 40:481-494.
6. Seden K., Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011, 6:514-526.
7. Hofmann W.P., Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011, 8:257-264.
8. Njoroge F.G., Chen K.X., Shih N.Y., Piwinski J.J. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 2008, 41:50-59.
9. Flint M., Mullen S., Deatly A.M., et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother 2009, 53:401-411.
10. Kwo P.Y., Zhao R. Boceprevir: a user's guide. Clin Liver Dis 2011, 15:537-553.
11. Rice C.M. New insights into HCV replication: potential antiviral targets. Top Antivir Med 2011, 19:117-120.
12. Gravitz L. Introduction: a smouldering public-health crisis. Nature 2011, 474:S2-S4.
13. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
14. Venkatraman S., Blackman M., Wu N., et al. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies. Bioorg Med Chem 2009, 17:4486-4495.
15. Ciesek S., Manns M.P. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011, 8:69-71.
16. Poordad F. Big changes are coming in hepatitis C. Curr Gastroenterol Rep 2011, 13:72-77.
17. Liu-Young G., Kozal M.J. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS 2008, 22:449-457.
18. Victrelis 2011, [package insert], Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Whitehouse Station, NJ, Accessed July 30, 2012. http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf.
19. Incivek 2012, [package insert], Vertex Pharmaceuticals Incorporated, Cambridge, MA, Accessed July 30, 2012. http://pi.vrtx.com/files/uspi_telaprevir.pdf.
20. Dore G.J., Matthews G.V., Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals. Curr Opin HIV AIDS 2011, 6:508-513.
21. Milazzo L., Antinori S. STAT-C: a full revolution or just a step forward?. Lancet 2010, 376:662-663.
22. Opar A. Excitement grows for potential revolution in hepatitis C virus treatment. Nat Rev Drug Discov 2010, 9:501-503.
23. Rice C. Perspective: miles to go before we sleep. Nature 2011, 474:S8.
24. Pawlotsky J.M. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011, 140:746-754.
25. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
26. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre Phase 2 trial. Lancet 2010, 376:705-716.
27. Chen K.X., Njoroge F.G. The journey to the discovery of boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C. Prog Med Chem 2010, 49:1-36.
28. Venkatraman S., Bogen S.L., Arasppan A., et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006, 49:6074-6086.
29. Zhang J, Gupta S, Rouzier R, et al. Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH 503034, in an oral capsule formulation. Abstract presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, 2005; San Francisco, Calif. Abstract 862.
30. Zeuzem S, Sarrazin C, Rouzier R, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-α). Abstract presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, 2005; San Francisco, Calif. Abstract 94.
31. Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype-1 peg-intron non-responders: Phase IB results. Abstract presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, 2005; San Francisco, Calif. Abstract 201.
32. Preston R, Alonso A, Feely W, et al. SCH 503034, an oral HCV protease inhibitor, is well-tolerated in patients with varying degrees of hepatic impairment. Abstract presented at: 42nd Annual Meeting of the European Association for the Study of the Liver; April 11-15, 2007; Barcelona, Spain. Abstract 545.
33. Treitel M., Marbury T., Preston R.A., et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet 2012, 51:619-628.
34. Ghosal A., Yuan Y., Tong W., et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011, 39:510-521.
35. Lange C.M., Sarrazin C., Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C-a new era in therapy. Aliment Pharmacol Ther 2010, 32:14-28.
36. Vermehren J., Sarrazin C. New HCV therapies on the horizon. Clin Microbiol Infect 2011, 17:122-134.
37. Nelson D.R. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients. Liver Int 2011, 31(Suppl 1):53-57.
38. Asselah T., Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011, 31(Suppl 1):68-77.
39. Susser S., Welsch C., Wang Y., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009, 50:1709-1718.
40. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
41. Jensen D.M. A new era of hepatitis C therapy. N Engl J Med 2011, 364:1272-1274.
42. Soriano V., Vispo E., Poveda E., et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011, 66:1673-1686.
43. Pockros P.J. Drugs in development for viral hepatitis: care and caution. Drugs 2011, 71:263-271.
44. Maddur H., Kwo P.Y. Boceprevir. Hepatology 2011, 54:2254-2257.
45. Asselah T. A sprint to increase response to HCV treatment: expectancies but caution. J Hepatol 2011, 55:1154-1158.
46. Charlton M., Leise M.D. Boceprevir (Victrelis) for HCV: V is for victory and very complex. Hepatology 2011, 54:1882-1886.
47. Sarrazin C., Rouzier R., Wagner F., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007, 132:1270-1278.
48. Degertekin B., Lok A.S. Update on viral hepatitis: 2007. Curr Opin Gastroenterol 2008, 24:306-311.
49. Pawlotsky J.M. Treatment of hepatitis C: don't put all your eggs in one basket!. Gastroenterology 2007, 132:1611-1615.
50. Pockros P.J. Drugs in development for chronic hepatitis C: a promising future. Expert Opin Biol Ther 2011, 11:1611-1622.
51. Schlutter J. Therapeutics: new drugs hit the target. Nature 2011, 474:S5-S7.
52. NDA 202258. Medical review(s) US Dept of Health and Human Services, Accessed July 31, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202258Orig1s000MedR.pdf.
53. Tungol A., Rademacher K., Schafer J.A. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J Manag Care Pharm 2011, 17:685-694.
54. Limave A.R., Draganov P.V., Cabrera R. Boceprevir for chronic HCV genotype 1 infection. N Engl J Med 2011, 365:176.
55. Kuntzen T., Timm J., Berical A., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008, 48:1769-1778.
56. Bartels D.J., Zhou Y., Zhang E.Z., et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naïve subjects. J Infect Dis 2008, 198:800-807.
57. Susser S., Vermehren J., Forestier N., et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011, 52:321-327.
58. Tong X., Bogen S., Chase R., et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008, 77:177-185.
59. Cubero M., Esteban J.I., Otero T., et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008, 370:237-245.
60. Curry S., Qiu P., Tong X. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods 2008, 153:156-162.
61. Romano K.P., Ali A., Royer W.E., Schiffer C.A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A 2010, 107:20986-200991.
62. Welzel T.M., Zeuzem S. Mixing and matching drugs: what makes sense?. Clin Liver Dis 2011, 15:657-664.
63. Chevaliez S., Asselah T. Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clin Res Hepatol Gastroenterol 2011, 35(Suppl 1):S31-S41.
64. Chase R., Skelton A., Xia E., et al. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral Res 2009, 84:178-184.
65. Tong X., Arasappan A., Bennett F., et al. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob Agents Chemother 2010, 54:2365-2370.
66. Brown N.A. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin Investig Drugs 2009, 18:709-725.
67. Nelson D.R. Hepatitis C drug development at a crossroads. Hepatology 2009, 50:997-999.
68. Fonseca-Coronado S., Escobar-Gutierrez A., Ruiz-Tovar K., et al. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. J Clin Microbiol 2012, 50:281-287.
69. Bae A., Sun S.C., Qi X., et al. Susceptibility of treatment-naïve hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 2010, 54:5288-5297.
70. Lenz O., Verbinnen T., Lin T.I., et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010, 54:1878-1887.
71. Vachon M.L., Dieterich D.T. The HIV/HCV-coinfected patient and new treatment options. Clin Liver Dis 2011, 15:585-596.
72. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology 2011, 54:3-5.
73. Seden K., Back D., Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2012, 65:1079-1085.
74. Muir A.J. Telaprevir for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther 2011, 9:1105-1114.
75. Weiss J.J., Alcorn M.C., Rabkin J.G., Dieterich D.T. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol 2012, 56:503-504.
76. Harrington P.R., Zeng W., Naeger L.K. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012, 55:1048-1057.
77. Cammà C., Petta S., Enea M., et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012 Mar 27, [Epub ahead of print].
78. Messori A., Fadda V., Maratea D., Trippoli S. Effect of discounting on estimation of benefits determined by hepatitis C treatment. World J Gastroenterol 2012, 18:3032-3034.
79. 2011 Drug Topics Red Book 2011, Thomson Medical Economics, Montvale, NJ.